NCT06082960View on ClinicalTrials.gov

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Solid Tumors
Interventions
DRUG

GS-9911

Tablets administered orally

DRUG

Zimberelimab

Administered intravenously

Trial Locations (6)

3000

Peter MacCallum Cancer Centre, Melbourne

37203

SCRI Oncology Partners, Nashville

78229

NEXT Oncology, San Antonio

South Texas Accelerated Research Therapeutics, LLC, San Antonio

06520

Smilow Cancer Hospital Phase 1 Unit, New Haven

M5G

University Health Network, Princess Margaret Cancer Centre, Toronto

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY